Liver artery therapy plus two drugs vs. standard treatment for advanced bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a three-drug combination (TACE plus two immune-related drugs) against a standard chemo-immunotherapy regimen for people with a liver cancer that can't be surgically removed. It aims to see if the new approach can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- Your cancer must be a type called intrahepatic cholangiocarcinoma, and it must not be removable by surgery (or has come back after treatment). It should not have spread outside the liver.
- You should not have had any previous chemotherapy or targeted therapy for this cancer, nor any treatment that goes directly into the liver artery.
- You need to be in fairly good overall health (your daily activities are not limited more than a little) and your liver function must be good enough (Child-Pugh class A).
- Your blood counts, kidney, liver, and thyroid function must be within certain safe ranges, as checked by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy directly to the liver, a targeted therapy pill, and an immunotherapy drug for people with advanced bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a combination of three treatments for people with advanced bile duct cancer that cannot be removed by surgery or has spread. The treatments include a chemotherapy infusion directly into the liver artery (HAIC), an immunotherapy drug (durvalumab), and a targeted therapy pill (lenvatinib). It aims to see if this triple therapy can shrink or control the cancer better than standard treatments.
This trial tests a combination of cryoablation (freezing tumors), lenvatinib (a targeted therapy), and QL1706 (an immunotherapy) for people with advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has worsened after initial treatment. The goal is to see if this combination can help stop the cancer from growing.
This trial tests a combination of immunotherapy (adebrelimab) and chemotherapy drugs for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that hasn't been treated yet. It aims to see if adding a targeted therapy (lenvatinib) improves outcomes.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
This trial is testing a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus a procedure called TACE (chemoembolization) against a targeted therapy pill (lenvatinib) plus TACE for people with advanced liver cancer. The goal is to see which approach works better to shrink tumors and improve outcomes.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.